Sam Waksal is back in the news with the announcement last week that his new private biotech company, Kadmon Pharmaceuticals, purchased privately held Pittsburgh-area Three Rivers Pharmaceuticals for its manufacturing and distribution.
Sam is a colorful sort and his return to the limelight after his conviction in the wake of insider trading of Imclone stock makes for good copy.
Here are some stories that are appearing this morning - BioJobBlog, Fierce Biotech, and PharmaGossip. Enjoy!
Posted by Bruce Lehr November 1st


Comments